Zacks Research Brokers Lift Earnings Estimates for Perrigo

Perrigo Company plc (NYSE:PRGO) – Equities research analysts at Zacks Research upped their FY2025 earnings per share estimates for Perrigo in a research note issued on Monday, February 16th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $2.77 for the year, up from their previous forecast of $2.76. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q4 2025 earnings at $0.80 EPS, FY2026 earnings at $3.00 EPS, Q3 2027 earnings at $0.81 EPS, Q4 2027 earnings at $0.84 EPS and FY2027 earnings at $3.18 EPS.

A number of other equities research analysts have also issued reports on the stock. Argus raised shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. Canaccord Genuity Group dropped their price objective on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. JPMorgan Chase & Co. cut their price objective on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. Finally, Jefferies Financial Group lowered their target price on Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a report on Monday, October 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.33.

Perrigo Stock Up 0.5%

NYSE PRGO opened at $14.97 on Thursday. The business has a fifty day moving average price of $14.30 and a 200 day moving average price of $17.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.44 and a current ratio of 2.51. The company has a market cap of $2.06 billion, a P/E ratio of -39.38, a P/E/G ratio of 1.34 and a beta of 0.39. Perrigo has a one year low of $12.17 and a one year high of $30.93.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 7.8%. Perrigo’s dividend payout ratio (DPR) is currently -305.26%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. increased its stake in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the last quarter. Huntington National Bank grew its holdings in shares of Perrigo by 237.8% during the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock worth $28,000 after purchasing an additional 742 shares during the period. Hantz Financial Services Inc. increased its position in shares of Perrigo by 101.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock worth $33,000 after purchasing an additional 620 shares during the last quarter. Kestra Investment Management LLC increased its position in shares of Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in Perrigo by 89.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after buying an additional 838 shares during the period. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Board approved a quarterly cash dividend of $0.29 per share (annualized $1.16) with an ex-dividend/record/payable schedule set for early March and March 24. A ~7.8% yield materially boosts the income case for PRGO and attracts yield-focused investors. Article Title
• Positive Sentiment: MarketBeat included Perrigo in a “high-yield” stock roundup, highlighting its ~7.9% yield and recent institutional buying — coverage that can drive fresh demand from income and deep-value investors. The article also frames PRGO as a cash-rich, high-yield option. Article Title
• Neutral Sentiment: Analysts and data providers (Zacks/others) have nudged near‑term and FY estimates modestly higher in recent research notes but maintain a cautious/“Hold” stance — a slight constructive signal but not a clear catalyst on its own.
• Neutral Sentiment: Research outlets report that analysts have published Q1 earnings predictions and that Perrigo is scheduled to report quarterly results this week — keep an eye on the release for guidance and any surprises. Article Title
• Negative Sentiment: Zacks’ earnings preview flags that Perrigo may face a Q4 earnings decline and lacks the setup for a clear beat, increasing the risk of a negative reaction if results or guidance disappoint. Article Title
• Negative Sentiment: MarketBeat notes Perrigo is navigating a class‑action lawsuit tied to an acquisition (Nestlé’s infant-formula plant) — a legal overhang that could pressure sentiment or create headline risk. Article Title

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.